NASDAQ: LIVN

LivaNova (LIVN) Stock Analysis & Forecast

Nov 13 close

$91.32+1.12 (+1.2%)

Gekko Brief

AI summaryNov 9 close

LivaNova's week was dominated by third-quarter results and raised guidance. The company reported revenue of $393.1 million, up 9.9%, with adjusted EPS of $1.23, beating consensus by $0.17. Growth was driven by double-digit gains in both the Cardiopulmonary and epilepsy businesses, prompting LivaNova to raise its full-year 2026 revenue growth guidance to 9%–10% and adjusted EPS guidance to $4.40–$4.50. Operating income for the quarter fell to $28.425 million from $54.012 million, which coverage attributed largely to higher litigation provision expenses. The company also presented at the UBS Global Healthcare Conference.

The stock closed at $92.61, up 2.9% on the day, and sits well above both its 50-day average of $79.52 and 200-day average of $73.65, with the shorter average above the longer one. The GekkoIndex reading of 42.2 places the stock in the Distribution zone, down 12.6 over five days. Price stands 10.5% above Gekko Fair Value of $83.78.

The next earnings date is 24 February 2027, 101 days away and outside a typical 20-trading-day hold. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows, and billionaire holders are recorded at zero. Analyst coverage from 6 firms is entirely rated buy, with a consensus target of $90.55, implying a -2.2% consensus upside from current levels. Seasonally, the next 20 trading days have averaged +2.8% over 5 years, rising in 2 of those years, a mixed historical pattern worth noting alongside the Distribution reading.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

LivaNova price vs fair value

$91.32$90.23Nov ’25May ’26Nov ’26
Close $91.32200-day averageGekko Fair Value $90.23

LivaNova quick facts

Market cap
$5.03B
P/E ratio
26.3
Forward P/E
18.7
EPS, TTM
$3.49
Revenue, TTM
$1.51B
Profit margin
13%
Dividend yield
—
Beta
0.92
Volume
742,275 avg 762,419
1-year return
+61.3%
Typical daily move
±4.4%
Typical 20-day move
±6.3%
50-day average
$80.32
200-day average
$74.18
Next earnings
Feb 24 before open
Shares outstanding
55.09M
52-week range
$52.37$99.38

LivaNova swing-trade checklist

LivaNova scores 3 supportive, 2 mixed and 0 headwinds across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive2 mixed0 headwinds

  • Trendsupportive

    Above 50 and 200-day

    Close $91.32 is above the 50-day ($80.32) and 200-day ($74.18) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    47.8, Neutral

    Reading 47.8 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuemixed

    1.2% above

    Price is within 5% of Gekko Fair Value (1.2% above).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 101 days

    Next report Feb 24, 2027, 101 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +3.8% on average

    From this point in the calendar, the next 20 trading days averaged +3.8% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

LivaNova stock chart and price history

LivaNova closed at $91.32 on Nov 13, 2026, +61.3% over the past year, inside a 52-week range of $52.37 to $99.38.

Close50-day average200-day averageVolume
LivaNova share price, past year, with 50-day and 200-day moving averages and volume$50$60$70$80DecJan 2026FebMarAprMayJunJulAugSepOctNov91.32

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+16.3%
3 months
+12.1%
6 months
+30.5%
1 year
+61.3%
The full LIVN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open LIVN in Gekko

Follow LivaNova through every session

Put LIVN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track LIVN in GekkoFree for 7 days. No credit card required.

About LivaNova

LivaNova develops and manufactures medical devices used in heart, lung, and nerve-related treatments. It is best known for its VNS Therapy System, an implanted device that stimulates the vagus nerve to help patients with drug-resistant epilepsy, hard-to-treat depression, and obstructive sleep apnea. The company also makes equipment used during heart-lung procedures, including oxygenators, heart-lung machines, and perfusion systems, along with temporary life support tools for cardiopulmonary and respiratory care.

The business is organized into three areas: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. Within Neuromodulation, LivaNova is also developing the VITARIA System, which applies vagus nerve stimulation to heart failure and remains in clinical development. Its customers include perfusionists, neurologists, neurosurgeons, and other physicians, along with hospitals and healthcare providers, reached through its own sales force and independent distributors. It also works with Verily on research into clinical biomarkers for depression.

LivaNova was founded in 1987 and is headquartered in London, United Kingdom. Its shares are listed on the NASDAQ under the ticker LIVN.

Listed
NASDAQ
Sector
Health technology
Industry
Medical specialties
Website
livanova.com

LivaNova GekkoIndex: the smart money zone

LivaNova’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 47.8, in the Neutral zone, up 6.8 points over five sessions.

010047.8Neutral

Up 6.8 points over five sessions, from the Distribution zone.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying49+0.6%+2.0%+3.1%+11.0%
Accumulation213+1.6%+2.5%+5.1%+7.4%
Neutral (current zone)398+0.1%+0.3%+0.4%+2.5%
Distribution40−1.0%−1.4%−1.3%−1.2%
Selling2Too few readings yet

Average LIVN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the LIVN price, zone by zone.Track LIVN in Gekko

Is LivaNova stock overvalued? Gekko Fair Value

LivaNova trades 1.2% above Gekko Fair Value of $90.23, so the shares are about fair value on Gekko’s estimate.

Gekko’s own estimate of what LivaNova shares are worth, recalculated every trading day.

$90.23

Gekko Fair Value, Nov 14, 2026

1.2% above fair value · About fair value

At the end of Aug 2026 the price was 7.1% below the estimate.

Gekko Fair ValueShare price, month end
$90$91Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open LIVN in Gekko

LivaNova insider and Congress trading

No open-market insider purchases were filed for LivaNova, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for LIVN in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every LIVN insider filing, plotted on the chart in Gekko.Open LIVN in Gekko

Congress trades last 90 days

No trades in LIVN were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for LIVN, plotted on the chart in Gekko.Open LIVN in Gekko

Buybacks

LivaNova has been buying back its own shares.

Bought back, quarter ended Dec 31, 2025
$805K
As a share of market cap
0.02%

From company filings.

Hedge funds and billionaires quarter ended Dec 31

0of the funds Gekko tracks hold LIVN.

0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko

LivaNova earnings: next date and track record

LivaNova reports on Feb 24, 2027, before the open (101 days away), and beat the EPS estimate in 8 of its last 8 reports.

8 of 8reports beat the EPS estimate
±4.6%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

+12.9%May ’24−5.8%Jul ’24−2.5%Oct ’24+1.7%Feb ’25−1.4%Apr ’25+1.3%Jul ’25−8.1%Nov ’25+2.8%Feb ’26

Last earnings call, Feb 25, 2026 AI summary

What they said
LivaNova delivered strong 2025 performance with double-digit revenue growth, marking the fifth consecutive year of double-digit EPS growth and third consecutive year of double-digit organic revenue growth. Cardiopulmonary segment achieved $785 million revenue with 13% growth, driven by mid-teens HLM growth and Essence machine placements representing 55% of annual units. The company continues strategic focus on obstructive sleep apnea as a high-growth expansion opportunity while maintaining core business strength.
Guidance
Management provided top-line guidance for 2026, with some planned Essence placements and tender activity shifted from Q4 2025 into 2026. Strong demand for consumables continues with supply constraints in oxygenators market.
ReportedEPSSurpriseRevenueSurpriseMove
Feb 25, 2026$0.86
est $0.80
+7.5%$360.9M
est $353.3M
+2.1%+2.8%
Nov 5, 2025$1.11
est $0.92
+20.8%$357.8M
est $342.7M
+4.4%−8.1%
Jul 29, 2025$1.05
est $0.87
+21.0%$352.5M
est $342.1M
+3.0%+1.3%
Apr 29, 2025$0.88
est $0.49
+79.6%$316.9M
est $330.9M
−4.2%−1.4%
Feb 19, 2025$0.81
est $0.80
+1.2%——+1.7%
Oct 30, 2024$0.90
est $0.72
+25.0%$318.1M
est $323.6M
−1.7%−2.5%
Jul 31, 2024$0.93
est $0.78
+19.2%$318.6M
est $304.2M
+4.7%−5.8%
May 1, 2024$0.73
est $0.49
+49.0%$294.9M
est $304.2M
−3.1%+12.9%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

LivaNova stock forecast and analyst price targets

Analysts’ average 12-month price target for LivaNova is $105.09, +15.1% from the last close, from 6 firms rating the stock in the last 90 days.

$105.09consensus 12-month target, +15.1% from the last close
Low $90High $120
Buy6
Hold0
Sell0

Each firm’s latest rating in the last 90 days: 6 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 9BarclaysBuy, maintained$120+31.4%
Nov 5BarclaysBuy, maintained$105+15.0%
Nov 5Mizuho SecuritiesBuy, maintained$115+25.9%
Nov 5Robert W. BairdBuy, maintained$111+21.6%
Nov 4NeedhamBuy, maintained$112+22.6%
+0.4%average 20-day move after past Neutral readings
+3.8%average move over the next 20 trading days in the last 5 years
±4.4%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

LivaNova seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, LivaNova averaged +3.8% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

−5.8%2021+11.3%2022+2.3%2023−1.6%2024+13.9%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−2.5%2 of 5
Next 10 trading days+0.6%2 of 5
Next 15 trading days+0.5%2 of 5
Next 20 trading days+3.8%3 of 5
Next 30 trading days+3.4%4 of 5

For scale, LIVN’s typical 20-trading-day move in either direction is about 6.3%.

LivaNova market cap and key statistics

LivaNova’s market cap is $5.03B, with a P/E ratio of 26.3 and revenue of $1.51B over the last twelve months.

Valuation

Market cap
$5.03B
P/E ratio
26.3
Forward P/E
18.7
EPS, TTM
$3.49
Gekko Fair Value
$90.23

Trading

Volume
742,275
Avg volume, 20 days
762,419
52-week high
$99.38
52-week low
$52.37
Shares outstanding
55.09M

Financials

Revenue, TTM
$1.51B
Profit margin
13%
Return on equity
15.5%
Quarterly earnings growth, YoY
−78.2%

Risk and income

Beta
0.92
Typical daily move
±4.4%
Typical 20-day move
±6.3%

LivaNova stock news this week

Coverage of LivaNova this week reads neutral: 2 positive, 4 neutral and 1 negative headlines.

News sentiment neutral

LivaNova peers

LivaNova’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
TMOThermo Fisher Scientific−0.2%Neutral15.0% above
ABTAbbott Laboratories+0.3%Neutral10.5% below
DHRDanaher0.0%Neutral4.7% above
ISRGIntuitive Surgical0.0%Neutral17.5% above
MDTMedtronic+0.7%Neutral14.2% below
SYKStryker−2.0%Neutral0.1% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Medical specialties

LivaNova stock FAQ

What is LivaNova’s market cap?

LivaNova’s market cap is $5.03B at the Nov 13, 2026 close of $91.32, with 55.09M shares outstanding. The shares trade on a P/E ratio of 26.3.

What is the LivaNova stock forecast?

The consensus analyst 12-month price target for LivaNova is $105.09, +15.1% from the last close. Of the 6 firms that rated the stock in the last 90 days, 6 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is LivaNova stock overvalued or undervalued?

On Gekko’s estimate LivaNova is about fair value: the Nov 13, 2026 close of $91.32 is 1.2% above Gekko Fair Value of $90.23. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does LivaNova report earnings next?

LivaNova is expected to report on Feb 24, 2027, before the market opens (101 days away). Analysts expect earnings of $0.98 per share on revenue of $389.2M. LivaNova beat the earnings estimate in 8 of its last 8 reports, moving 4.6% on average across the report.

What is LivaNova’s 52-week high and low?

LivaNova’s 52-week high is $99.38 and its 52-week low is $52.37; it closed at $91.32 on Nov 13, 2026, +61.3% over the past year.

Is LivaNova stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, earnings risk and seasonality), 2 as mixed (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See LivaNova the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.